Viridian Therapeutics IncChange company Symbol lookupSelect an option...VRDN Viridian Therapeutics IncCRIS Curis IncPIXY ShiftPixy IncRVLP RVL Pharmaceuticals PLCNAUT Nautilus Biotechnology IncBOF BranchOut Food IncSPRC Scisparc LtdNRSN Neurosense Therapeutics LtdACNT Ascent Industries CoFATH Fathom Digital Manufacturing CorpGo
Viridian Therapeutics, Inc. is a biotechnology company focused on discovering and developing medicines for serious and rare diseases. The Company is engaged in developing three product candidates, VRDN-001, VRDN-002, and VRDN-003, that is developed for intravenous (IV) or subcutaneous administration to treat patients who suffer from thyroid eye disease (TED). Its lead product candidate, VRDN-001, is a differentiated humanized monoclonal antibody targeting insulin-like growth factor-1 receptor (IGF-1R), a clinically and commercially validated target for the TED. It has initiated a Phase I/II clinical trial of VRDN-001. Its second product candidate, VRDN-002, is a distinct IGF-1R antibody that incorporates half-life extension technology, and is designed to support administration as a convenient, low volume, subcutaneous injection to treat patients who suffer from TED. VRDN-003 is an anti-IGF-1R monoclonal antibody with the same amino acid sequence as VRDN-001.
Postmarket |
|
|
| ||
Market Hours |
|
|
|
|
|
Upcoming Events
Past Earnings
GAAP vs. Non-GAAP Earnings
TD Ameritrade displays two types of stock earnings numbers, which are calculated differently and may report different values for the same period. GAAP earnings are the official numbers reported by a company, and non-GAAP earnings are adjusted to be more readable in earnings history and forecasts.
| Date | Event description | Earnings per share actual | Earnings estimate range | Previous year's actual |
|---|---|---|---|---|
| August 8, 2023 | Q2 2023 Earnings Release | -$1.27 | -$1.69 to -$0.97 | -$1.06 |
| May 9, 2023 | Q1 2023 Earnings Release | -$1.61 | -$1.23 to -$0.82 | -$0.98 |
| March 8, 2023 | Q4 2022 Earnings Release | -$1.13 | -$0.94 to -$0.50 | -$1.32 |
| November 14, 2022 | Q3 2022 Earnings Release | -$0.86 | -$1.24 to -$0.48 | -$1.25 |
Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.
, , , Copyright © 2023. All rights reserved.
Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.
Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.